Abstract
29
resistance independent of significant enlargement (Nickel, 1999) . Age-related decrease in detrusor 30 contractility and primary detrusor over-activity contribute significantly to lower urinary tract symptoms.
31
Recently, prostatic inflammation has been found to be associated with prostatic enlargement, severity 32 of LUTS and symptomatic progression. That is the focus of this review. 
134
The new awareness of inflammation's role in BPH has led to speculation that established medical 
140
The phosphodiesterase type-5 (PDE5) inhibitor tadalafil has been approved for treatment of BPH- 
